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Genetic events speciﬁc to the pathogenesis of malignancy can oﬀer clues to the tumorigenesis process. The objective of this study
was to identify gene alterations that diﬀerentiate tumor and nontumor lesions in squamous head and neck cancer (HNSCC). DNA
from 220 primary HNSCC with concurrently present tumor and nontumor lesions from the same patient was interrogated for ge-
nomic alterations of loss or gain of copy. Conditional logistic regression dealt with tumor and non-tumor records within a patient.
Of113genes,53hadunivariateeﬀects(P<0.01),ofwhich16genesremainedinthemultivariablemodelwithP<0.01.Themodel
had a C-index (ROC) of 0.93. Loss of CDKN2B and gain of BCL6, FGF3,a n dPTP4A3 predicted tumor. Loss of BAK1 and CCND1
and gain of STCH predicted nontumor. This highly powered model assigned alterations in 16 genes speciﬁc for malignant versus
nonmalignant lesions, supporting their contribution to the pathogenesis of HNSCC as well as their potential utility as relevant tar-
gets for further evaluation as markers of early detection and progression.
1.Introduction
Knowledge of the genetic mechanisms that drive cancer
growth and development is important in understanding the
pathogenesis of malignancy and provides insights into the
tumorigenesis process. The underlying hypothesis is that be-
havior of tumor cells is determined by genetic changes that
alter cell growth, cell diﬀerentiation, programmed cell death,
and cell migration. Cancer is the result of transformation
from a normal to a malignant cell that results from accumu-
lated mutations. Acquisition of a fully malignant phenotype
in colon cancer is thought to occur because of multiple steps
whose targets are alterations of growth-promoting onco-
genes and growth-inhibiting cancer suppressor genes. The
evolution in transformation from a normal squamous epi-
thelial cell to a cancer cell is likewise assumed to require sev-
eral steps, some deﬁned by genetic alteration.
Genetic alterations provide means of identifying tumor
cells as well as deﬁning changes that presumably determine
biological diﬀerences from their normal counterparts. Chro-
mosome aberrations have served as landmarks to identify
cancer genes in many tumor types; however, individual gene
locialteredintumorscannotbededucedsolelyfromthetype
of chromosome rearrangement [1]. Historically, the molecu-
lar pathogenesis of cancer has been teased out one gene at a
time. Recent high-throughput genomewide candidate strat-
egies such as the multiplex ligation-dependent probe ampli-
ﬁcation (MLPA) assay [2] to identify speciﬁc genes for gain
and loss concurred with chromosomal aberrations and pro-
vide a novel index to estimate the extent of genomic abnor-
mality with disease progression [1].
Molecular genetic prognosticators can inﬂuence preven-
tion, diagnosis, appropriateness of adjuvant chemotherapy,
and, possibly, the chemotherapeutic regimen of cancer pa-
tients. Dissecting out processes speciﬁc to the pathogenesis
of malignancy can distill key genetic biomarkers of HNSCC
etiology, transformation, and progression.
Inthisstudy,inaprimaryHNSCCcohortof220patients,
with both tumor and nontumor lesions within a biopsy (tu-
mor and nontumor from the same patient), we examined
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predictive models to discriminate malignant from nonma-
lignant lesions.
2. Methods
2.1. Patient Cohort. Cohort subjects were male and female
patients 18 years and older who underwent a HNSCC tissue
biopsy at the Henry Ford Health System from 1986–2006.
The use of formalin-ﬁxed paraﬃn-embedded tissue blocks
frompatientswithbothtumorandnontumorrecordswithin
the same biopsy and the collection of related patient infor-
mation were approved by the Henry Ford Health System In-
stitutional Review Board (IRB) Committee.
In the event a study subject had more than one eligible
biopsy over the course of the study period, the primary bi-
opsy was the index biopsy and the pathology report date
marked the study enrollment (index) date. Cohort subjects
missing biopsy tissue blocks or insuﬃcient tissue for molec-
ular analysis were excluded.
2.2. Histopathology. Pathology review of paraﬃn-embedded
tissue sections captured all lesion types in a biopsy to include
normal squamous epithelium, squamous dysplasia whether
classiﬁed as mild, moderate, or severe/carcinoma in situ, and
tumor. Severe dysplasia and carcinoma in situ lesions were
g r o u p e dw i t ht u m o ra n dc o n s i d e r e da sm a l i g n a n to u t c o m e s .
2.3. Molecular Analysis
2.3.1. Processing Lesion Specimens for Molecular Analysis.
DNA was obtained from either whole 5 micron tissue sec-
tions (if the tissue block contained predominantly tumor or
nontumortissue)orfrommicrodissectedtissueaspreviously
described [3]. Brieﬂy, concurrently present tumor (severe
dysplasia, carcinomain situ,tumor) andnontumor (normal,
mild/moderate dysplasia) lesions in the same paraﬃn-em-
bedded formalin ﬁxed tissue block were marked by the path-
ologist and individual lesions were microdissected from 5
micron sections mounted on glass slides using a single-use
disposable scalpel blade under a dissecting microscope. This
procedure minimizes mixing of normal and tumor subpop-
ulations and yields lesion and tumor samples estimated to
be at least 90% free from contamination with normal cells
[3, 4].
2.3.2. The Multiplex Ligation-Dependent Probe Ampliﬁcation
(MLPA) Assay. MLPA has several advantages. It establishes
the copy number of up to 41 nucleic acid sequences in one
single reaction. MLPA probes are able to discriminate bet-
ween sequences that diﬀer in only one nucleotide. Moreover,
MLPA reactions require a minimum of only 20ng human
DNA making it especially amenable for PCR of DNA from
formalin-ﬁxed paraﬃn-embedded head and neck tissues [3–
5].
Starting with, approximately, 20–50ng of genomic DNA,
for each subject in the cohort, DNA from tumor and nontu-
mor is ampliﬁed for 122 probes (113 unique genes associated
with cancer including HNSCC) as separate sets of three
reactions (probe sets p005, p006, p007, MRC Holland, Am-
sterdam). Brieﬂy, DNA, diluted with water to a total volume
of 5μL, is denatured and fragmented by heating for 5 min-
utes at 98◦C in a thermocycler. Binary MLPA probes are add-
ed and allowed to hybridize to their targets during an 16hr
incubation at 60◦C, followed by the addition of dilution buf-
ferandaligaseenzyme(MRCHolland,Amsterdam).During
the 15-minute incubation at 60◦C, the two parts of a probe
become ligated to each other and become an ampliﬁable
molecule if the complementary sequence is present in
theDNAsample.ThisisfollowedbytheadditionofPCRpri-
mers, dNTPs and Taq polymerase, followed by the following
cycles: one at 1min 95◦C, 10 cycles: 30sec 95◦C, 30sec 70◦C,
1min72 ◦C;30cyclesat30sec95◦C,30sec60◦C,1min72◦C.
T h es a m ep r i m e rp a i r ,o n eo fw h i c hi st a g g e dw i t haﬂ u o r e s -





cribed [1, 3, 4, 6–8].
2.4.StatisticalAnalysis. Conditionallogisticregressionmod-
eling was used to address tumor and nontumor lesions with-
in the primary biopsy in an HNSCC patient. Analysis began
by testing individual genes as risk predictors/discriminators
for tumor and nontumor (univariate analysis). Genes with
individual risks in a univariate analysis (P<0.01) were can-
didates for the ﬁrst multivariable model. Prior to multivari-
ablemodeling, geneswereevaluatedfortheir correlation and
missing values. Highly correlated genes (correlation coeﬃ-
cient [r] > 0.7) or genes with larger missing values (>5%)
were ﬁtted separately along with other uncorrelated (r < 0.7)
genes. The stepwise model selection was considered. The
ﬁnal model included genes with P<0.01 along with odds
ratios for loss or gain as risk predictors. The C-index/ROC
(the receiver operating characteristic {ROC} curve), in a
range of 0 to 1, is a measure of the model’s predictive ability,
where0.5indicatesnodiscriminationand0.7orgreaterindi-
cates that the model is predictive.
3. Results and Discussion
3.1. Results. Matched tumor and nontumor lesions within
each patient in the 220 primary HNSCC cohort comprised
a total of 1076 tissue records. There were 504 normal/mild/
moderate dysplasia lesions (495: normal squamous epithe-
lium, 6: mild dysplasia, 3: moderate dysplasia), and 572 tu-
mor lesions (568: tumor, 1: severe dysplasia, 3: carcinoma in
situ (CIS)). Squamous mucosal dysplasia whether classiﬁed
as mild, moderate, or severe/carcinoma in situ is considered
intraepithelial neoplasia, and, as a precursor lesion group is
separate from normal and tumor. The number of precursor,
lesions is very small (13) in comparison to normal epithe-
lium (495) and carcinomas (568). Of the 572 tumor lesions,
193 (34%) were laryngeal, 170 (30%) were oral cavity, 151
(26%) were pharyngeal (oropharyngeal/hypopharyngeal),Journal of Oncology 3
Table 1: Genes alterations that predict malignant (M, bolded) and nonmalignant (NM, italicized).
Eﬀect Chromosome Odds ratio estimate Lower CL∗ Upper CL
§MCTNNB1 l o s sv e r s u sn o r m a l 3 p 2 2 2.682 1.394 5.162
NMCTNNB1 gain versus normal 0.323 0.147 0.71
BCL6 loss versus normal 3q27 0.55 0.27 1.12
MBCL6 gain versus normal 8.989 3.155 25.612
§MIL2 loss versus normal 4q26 3.697 1.774 7.705
NMIL2 gain versus normal 0.149 0.055 0.407
NMBAK1 l o s sv e r s u sn o r m a l 6 p 2 1 . 3 0.262 0.103 0.666
BAK1 gain versus normal 0.438 0.192 0.999
§MLTA l o s sv e r s u sn o r m a l 6 p 2 1 . 3 2.156 1.172 3.965
NMLTA gain versus normal 0.266 0.108 0.655
§NMFGFR1 l o s sv e r s u sn o r m a l 8 p 2 1 0.275 0.126 0.598
MFGFR1 gain versus normal 5.555 1.689 18.267
§NMPRKDC loss versus normal 8q11 0.276 0.11 0.692
MPRKDC gain versus normal 5.449 2.09 14.206
§NMMYC loss versus normal 8q24.12 0.221 0.097 0.503
MMYC gain versus normal 2.218 1.136 4.332
PTP4A3 loss versus normal 8q24.3 0.493 0.214 1.135
MPTP4A3 gain versus normal 12.158 3.461 42.71
§MCDKN2A loss versus normal 9p21 1.845 1.013 3.362
NMCDKN2A gain versus normal 0.14 0.056 0.35
MCDKN2B loss versus normal 9p21 3.256 1.676 6.325
CDKN2B gain versus normal 1.168 0.442 3.087
MLMO2 loss versus normal 11p13 4.977 2.16 11.466
LMO2 gain versus normal 0.573 0.205 1.607
FGF3 loss versus normal 11q13 0.882 0.447 1.741
MFGF3 gain versus normal 7.819 3.286 18.604
NMCCND1 loss versus normal 11q13 0.403 0.22 0.736
CCND1 gain versus normal 1.239 0.634 2.421
STCH loss versus normal 21q11.1 1.788 0.833 3.839
NMSTCH gain versus normal 0.124 0.043 0.359
§MTFF1 loss versus normal 21q22.3 3.019 1.514 6.02
NMTFF1 gain versus normal 0.08 0.024 0.268
∗CL: conﬁdence limit, §: genes with loss and gain signifying aneuploidy.
and 58 (10%) were lesions in the other category (nasophar-
ynx, nasal cavity, paranasal sinuses).
The 1076 lesions were distributed among 932 tissue
blocks, of which 434 (47%) had tumor lesions only, 363
(39%) had nontumor lesions only, and 135 (14%) tissue
blocks had both tumor and nontumor lesions. Within a pa-
tient, the number of nontumor lesions ranged from 1 to 6
and from 1 to 7 for tumor lesions. Of the 220 patients with
both tumor and nontumor within the same patient, 35
(16%) had 1 tumor and nontumor record, 28 (13%) had 2
tumor and nontumor records, 27 (12%) had 3 tumor and
nontumor records.
Fiftypercentofcohort(110/220)subjectswereCaucasian
American (CA), 38% (84/220) were self-reported as African
American (AA), 4% (9/220) were non-CA/non-AA (His-
panic: 2, Asian Paciﬁc Islander: 2, Middle Eastern: 3, other:
2), and, in 8% (17/220), race was missing. Of the 220
patients, 25% (55/220) were female and 75% (165/220) were
male.
The missing value for each gene was in a range of 0% to
4.2%. Of the 113 unique genes (selected based on their asso-
ciation with cancer including HNSCC), 53 genes had uni-
variate eﬀects (P<0.01) and were considered as the candi-
date genes for multivariable analyses. After the stepwise
model selection, 16 genes remained in the multivariable
model (P<0.01) (Table 1). The model had a C-index (re-
ceiver operating characteristic (ROC)) of 0.93.
The 16 genes in the ﬁnal model with alterations of loss
and/or gain accounted for loci along 7 chromosomes: 3, 4,
6, 8, 9, 11, and 21 (Table 1). Of these, 50% were altered in
both tumor and nontumor, with loss or gain reﬂective of
chromosomal aneuploidy. This copy number instability
favored loss of CDKN2A (9p21), CTNNB1 (3p21), IL2
(4q26), LTA (6p21.3), and TFF1 (21q22.3) in tumor, with4 Journal of Oncology
corresponding gain in nontumor lesions, and gain of FGFR1
(8p21), MYC (8q24.12), and PRKDC (8q11) in tumor, with
corresponding loss in nontumor (Table 1).
Loss of CDKN2B (9p21) and LMO2 (11p13) and gain of
BCL6 (3q27),FGF3(11q13),andPTP4A3(8q24.3)predicted
tumor. Loss of BAK1 (6p21.3) and CCND1 (11q13) and gain
of STCH (21q11.1) predicted nontumor (Table 1).
Analysis excluding the 6 mild dysplasia and 3 moderate
dysplasia lesions from the nontumor group and the 1 severe
dysplasia lesion and 3 CIS from the tumor group generated
an identical multivariable model outcome.
3.2. Discussion. Cancerous tissue in most cases has a dis-
tinctive appearance under the microscope. Distinguishing
traits include a large number of dividing cells, variation in
nuclear size and shape, variation in cell size and shape, loss
ofspecializedcellfeatures,lossofnormaltissueorganization,
and a poorly deﬁned tumor boundary. Biopsy and micro-
scopical examination can also distinguish malignancy, pre-
cursor lesions of carcinoma in situ, mild, moderate, and
severe dysplasia, and less reliably, hyperplasia, from normal
appearing tissue.
In the multistep process of tumorigenesis, hyperplasia,
whichreferstotissuegrowthbasedonanexcessiverateofcell
division, leading to a larger than usual number of cells but
with a normal orderly arrangement of cells within the tissue,
and considered reversible, is thought to precede dysplasia.
Dysplasia, an abnormal type of excessive cell proliferation
characterized by loss of normal tissue arrangement and cell
structure, may revert to normal behavior, but, occasionally,
these lesions gradually become malignant. Distinguishing
true precursor lesions on the basis of morphology alone is
often unreliable. In the molecular progression of HNSCC,
normal or minimal dysplasia often harbors abnormal geno-
types [9], which do not necessarily correlate with observable
changes in phenotype (morphology) [10, 11].
Inthisstudy,16genealterationswithsigniﬁcantdiscrim-
inatory ability diﬀerentiated malignant HNSCC from non-
malignant tissue. For matched tumor and nontumor lesions
from the same patient within the 220 primary HNSCC study
cohort, examined for alterations in 113 unique genes with
association to head and neck cancer, molecular alterations in
“normal” appearing epithelium within the environment of a
malignant biopsy harbored genotypic abnormalities that set
them apart from malignant tissue.
T h e1 6g e n e si nt h eﬁ n a lm o d e ls p a nl o c ia l o n g7c h r o -
mosomes: 3p21: CTNNB1, 3q27: BCL6; 4q26: IL2; 6p21.3:
BAK1andLTA;8p12:FGFR,8q24.12:MYC,8q24.3:PTP4A3;
9p21: CDKN2A, CDKN2B; 11p13: LMO2, 11q13: CCND1,
FGF3; 21q11.1: STCH, 21q22.3: TFF1. Gene alterations at
these loci restate reported cytogenetic [7, 12–22] and mole-
c u l a r l ya l t e r e dr e g i o n sb yL O Ha n da r r a yC G Hs t u d i e si n
HNSCC [1, 5, 7, 23–28]. Additionally, copy number loss in
tumor and corresponding gain in nontumor, and vice versa,
advocate aneuploidy events. The latter are highlighted for
loss of CDKN2A (9p21), CTNNB1 (3p22), IL2 (4q26), LTA
(6p21.3), and TFF1 (21q22.3) in tumor, with corresponding
gain in nontumor lesions, and gain of FGFR1 (8p12), MYC
(8q24.12), and PRKDC (8q11) in tumor, with corresponding
loss in nontumor. Chromosomal instability occurs early
along the tumorigenesis continuum and aneuploidy at the
9p21 locus aﬀecting corresponding loss and gain in tumor
and normal tissue, respectively, concurs with the proposed
postulated model of molecular carcinogenesis for HNSCC
[29].
InHNSCC,chromosomalaberrationsonthelongarmof
chromosome 3, resulting in gain of distal 3q segments, have
been reported as recurring karyotypic alterations [22]. Gain
of 3q is supported by increased copy number (3-4 copies) of
PIK3CA at 3q26.3, MME (3q25.1), and BCL6 genes at 3q27
[1] in HNSCC. In this study, gain of BCL6 was signiﬁcantly
associated with tumor lesions. The protein encoded by BCL6
is a zinc ﬁnger transcription factor and acts as a sequence-
speciﬁc repressor of transcription.
Another chromosome 3 gene, CTNNB1 (catenin beta-1)
in the short arm at 3p21, is an adherens junction protein,
closely associated with adhesion, invasion, and metastasis in
diﬀerent types of tumors, including SCC of the tongue [30].
The3p21regionhadthehighestrateofallelicdeletion(63%)
in HNSCC [31]a n di ss u p p o r t e db yl o s so fCTNNB1 in tu-
mor lesions in this study. Corresponding gain of CTNNB1
copy number in nontumor lesions underscores chromoso-
mal instability and ensuing aneuploidy as early events in the
tumorigenesis process.
Loss and corresponding gain of IL2 at 4q26 was signiﬁ-
cantly associated with tumor and nontumor lesions, respec-
tively. The IL2 protein is produced by T cells in response to
antigenic or mitogenic stimulation and is required for T-cell
proliferation and other activities crucial to regulation of the
immune response.
BAK1 (6p21.3) is a proapoptotic member of the BCL-2
family of genes that are involved in regulation of program-
med cell death, and its increased expression had poorer dis-
ease-speciﬁc survival in oral tongue squamous cell carcino-
mas [32]. As a corollary to increased expression [32], in this
study, loss of BAK1 was a nontumor-speciﬁc event.
Gene alterations were noted for 4 genes on chromosome
8, three on 8q and one on 8p. Gains or ampliﬁcations involv-
ing chromosome arm 8q are one of the most recurrent chro-
mosomal alterations in head and neck tumors. The human
protein tyrosine phosphatase type IVA, member 3, also
known as PTP4A3, is located at 8q24.3 [33]. The protein en-
coded by this gene is a cell signaling molecule that partici-
pates in every aspect of cellular physiologic and pathologic
processes [33]. Recent studies [34, 35] suggest that an excess
PTP4A3 may play a key role in the acquisition of metastatic
potential of tumor cells. This study further supports gain
of PTP4A3 as a malignancy-associated alteration [36]i n
HNSCC.
The MYC oncogene, located at 8q24.12, encodes a trans-
cription factor that plays a key role in cell proliferation, diﬀ-
erentiation, and apoptosis [37]. Gain of MYC was signiﬁcant
for laryngeal tumor progression [38], and the concomitant
over expression of MYC and p53 oncogenes had worse dis-
ease-free survival suggesting a role for p53 and MYC genes
in progression of HNSCC [39]. In this study, gain of MYC
signiﬁcantly discriminated tumor from nontumor tissue.Journal of Oncology 5
The corresponding loss of MYC copy number in nontumor
suggests aneuploidy as a likely destabilizing event.
DNA double-strand breaks repair pathway has been im-
plicated in maintaining genomic integrity via suppression of
chromosomal rearrangements. PRKDC (protein kinase,
DNA-activated, catalytic polypeptide) is associated with
chromosomal instability with risk of breast and uterine cer-
vix cancer [40]. In this study, genomic instability at the 8q11
locus favored gain of PRKDC copy number in tumor and
corresponding loss in nontumor.
FGFR-1, located at 8p21, had gain of copy number in
tumor and corresponding loss in nontumor. FGFR-1 expres-
s i o nh a sb e e nd e t e c t e di nt h y r o i dc a r c i n o m a[ 41]a n di no r a l
squamous cell carcinomas (OSCC). Ampliﬁcation of FGFR1
detected by FISH analysis on OSCC tissue microarray sec-
tions contributed to oral carcinogenesis at an early stage of
development [42].
Genetic alterations at the 9p21 locus have been linked to
malignant progression in HNSCC [43, 44]. CDKN2A and
CDKN2B genes map to 9p21 and are in tandem, spanning
a region of approximately 80kb [45, 46]. Inactivation of the
CDKN2A (p14), CDKN2B (p15), and CDKN2A (p16) genes
is a frequent event in human oral squamous cell carcinomas
[47]. The main modes of p16INK4a inactivation in HNSCC
are known to include homozygous deletions (40–60%), mu-
tations (15–20%), and gene hypermethylation events (5%)
[47–49]. This study supports loss of CDKN2A and CDKN2B
genes as independent predictors of tumor in HNSCC pa-
tients.
Ampliﬁcation of the 11q13 amplicon is driven by multi-
ple genes, rather than only one or two genes at this site [50–
52]. In this study, four genes at the 11q13 locus were inter-
rogated, CCND1, FGF3, EMS1,a n dRELA,o fw h i c h ,g a i n
of CCND1, FGF3,a n dEMS1 were univariate (P<0.0001)
predictorsoftumor.Multivariateanalysis(P<0.01)retained
gain of FGF3 in tumor and loss in nontumor, supporting in-
volvement of ampliﬁcation/gain of copy number of this gene
in HNSCC [53, 54]. FGF3 belongs to the basic ﬁbroblast
growthfactor(FGF)genefamilywitharoleinseveralimpor-
tant cellular processes, including regulation of cell growth
and division, determination of cell type, formation of blood
vessels, wound healing, and embryo development. In
HNSCC,FGF3hadasigniﬁcantlyhigherfrequencyofampli-
ﬁ c a t i o ni nh yp o p h a ry n g e a lt u m o r s[ 55]. Loss of CCND1 was
signiﬁcantly associated with nontumor lesions in this study
cohort, suggesting genomic instability/chromosomal ane-
uploidy events in the direction of corresponding gain of
CCND1 in tumor lesions (P<0.001, univariate analysis).
Overexpression and/or ampliﬁcation of CCND1 is reported
in 35%–65% of patients with HNSCC and is associated with
poor prognosis [56–58]. Its expression is deregulated in pre-
invasive lesions adjacent to invasive tumors and is associated
with increased chromosomal instability and the likelihood of
subsequent gene ampliﬁcation. [59, 60]L o s so fCCND1 copy
number in nontumor tissues in this study may reﬂect very
early genomic instability at this chromosomal locus and sup-
ports reports of CCND1 deregulation in preinvasive lesions
oftheupperaerodigestivetractwithassociatedincreasedrisk
for the development of cancer accompanied by histologic
progression during and after chemopreventive intervention
[61, 62]. Though corresponding gain of CCND1 was not
retained in the ﬁnal multivariate model, 24% of tumor
lesions had copy number gain. Loss of LMO2 (also known as
RBTN2 and TTG2), located at 11p13, predicted tumor le-
sions.Thisgeneencodesatranscriptionalcofactorcriticalfor
the development of hematopoietic stem cells [63].
Gain of copy number at two 21q loci, TFF1 (21q22.3)
and STCH (21q11.1), predicted nontumor lesions, and cor-
responding loss of TFF1 was a signiﬁcantly associated with
tumor lesions. Loss of TFF1 in tumor lesions with corre-
spondinggaininnontumorsupportsgenomicinstabilityasa
concertedearlytumorigenesisevent.STCH (stress70protein
chaperone), at 21q11.1, a member of the heat shock protein
70 (HSP70) superfamily with cell-protective functions, was
previously identiﬁed as a candidate gene for susceptibility to
stomachcancerbygenetic analyses[64].STCH copy number
gain in nontumor lesions remained in the ﬁnal model as an
independent predictor of nonmalignant tissue (correspond-
ing loss in tumor lesions remained a univariate variable,
P<0.001).
The model’s discriminatory abilities (C-index/ROC of
0.93) support molecular distinctiveness of malignant versus
nonmalignant tissue with signiﬁcant predictive power. The
latter is of particular signiﬁcance because normal samples
from patients with head and neck cancer, especially in the
neighborhood of the tumor, can be genetically altered (ﬁeld
cancerization). The proximity of tumor and nontumor le-
sions, therefore, makes it harder to discriminate between
these two entities. However, the relatively large number of
tissue records (n = 1,076) from 220 patients was a factor in
overcoming these challenges to yield a robust model with
excellent ability (C-index = 0.93) to discriminate malignant
and nonmalignant tissue within the same patient.
Genetic alterations at 16 chromosomal loci underscore
the association of already known genes as well as newer gene
targets in HNSCC pathogenesis. The sixteen gene predictors
spanning loci along 7 chromosomes cover an array of essen-
tial functions that ensure normal homeostasis to include
DNA repair (PRKDC), initiation of carcinogenesis (TFF1),
immune surveillance (IL2, LTA), cell cycle regulators
(CDKN2A, CDKN2B), apoptosis (BAK1, STCH), regulation
of cell proliferation and diﬀerentiation (CCND1, FGF3,
MYC), transcription factors (BCL6), stem cell hematopoiesis
(LMO2), adhesion, invasion and metastasis (CTNNB1,
FGFR1), and acquisition of metastatic potential of tumor
cells (PTP4A3), implicating these genes as key players in the
tumorigenesis continuum.
4. Conclusion
Genomic instability, a hallmark of malignant transforma-
tion, promotes a wide range of mutations, including chro-
mosome deletions, gene ampliﬁcations, translocations, and
polyploidy [40]. In this study, the directional loss and gain
for several genes underscored the contribution of aneuploidy
in early HNSCC tumorigenesis. Our data support distinct6 Journal of Oncology
genetic signatures that discriminate malignant and nonma-
lignant tissue in HNSCC. The 16 gene alteration signature in
this study suggests ﬁnely choreographed genomic instability
events to achieve biological distinctiveness, providing clues
to the drivers in invasive cancers as well as insight into gene
rearrangements that might arise in nonmalignant lesions.
T h eg e n es e t sm e e ts t a t i s t i c a lr i g o rt os e g r e g a t em a l i g n a n t
squamous carcinoma lesions from nonmalignant lesions,
providing an opportunity for researchers to investigate these
cancer-associated genes as potential targets of therapy either
as single targets or as sets of targets when these occur in the
same cancer lesion.
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